Posterior reversible encephalopathy syndrome in immunocompromised children - A single-center study from South India

• Published in: Journal of neurosciences in rural practice 2024-04, Vol.15 (2), p.365-369, Article 365
• Main Authors: Gaddam, Sudeep, Kodandapani, Rajesh, Mani, Nikhita, Jayaraman, Dhaarani, Abirami, B Nikitha
• Format: Article
• Language: English
• Subjects: Brief Report
• ISSN: 0976-3147; 0976-3155
• DOI: 10.25259/JNRP_390_2023

This study describes the profile of children diagnosed with posterior reversible encephalopathy syndrome (PRES) in the pediatric hematology oncology unit and highlights the clinical features of PRES in immunosuppressed children. This retrospective study included 10 children diagnosed with PRES with a mean age of 6.8 years. Acute lymphoblastic leukemia was the most common primary diagnosis followed by post-hematopoietic stem cell transplant patients. Most cases of PRES occurred within one month of treatment initiation. Hypertension was noted in all at the time of diagnosis. Neuroimaging revealed bilateral lesions with parietal and occipital lobe involvement being the most common. All patients received corticosteroids as part of treatment for primary diagnosis. Controlling blood pressure was critical in managing PRES. Consideration of PRES as a clinical possibility in pediatric hematology oncology unit in children presenting with symptoms such as headache, seizures, and visual disturbances will aid in early diagnosis after ruling out other causes of these symptoms.